Belite Bio (ADR) (BLTE)
Develops oral investigational therapies for retinal and metabolic diseases.
Something off on this page? Send us feedback.
Develops investigational small-molecule therapies for degenerative retinal diseases and metabolic disease. It has no approved products or product-sales revenue; its lead oral candidate, tinlarebant, targets Stargardt disease and geographic atrophy, while LBS-009 targets metabolic disease.
Develops small-molecule therapies for degenerative retinal diseases and metabolic disease. Tinlarebant (LBS-008), a once-daily oral RBP4 antagonist, is its lead candidate for Stargardt disease and geographic atrophy; LBS-009 is a metabolic-disease program.
Clinical-development infrastructure spans the United States, Australia, Hong Kong, Shanghai, Switzerland and Japan. An in-house discovery and R&D team works with CROs, CMOs, investigators and clinical-trial sites.
Tinlarebant's STGD1 NDA submission is complete, but the therapy remains investigational, while DRAGON II and PHOENIX continue. With no approved products or product-sales revenue, development and commercialization depend on regulatory review, external clinical partners and further financing.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | Mizuho Securities | Target | Target: $220 | Target: $234 |
| Sep 8, 2026 | H.C. Wainwright | Target | Target: $214 | Target: $245 |
| Sep 4, 2026 | Canaccord Genuity | Target | Target: — | Target: $303 |
| Aug 14, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $191 | Target: $206 |
| Aug 14, 2026 | Cantor Fitzgerald | Reiterate | Rating: —Target: — | Target: $270 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $0 · Total debt $0 · Total assets $791.6M · Shareholders' equity $776.6M
- Revenue
- $0
- Operating income
- −$34.9M
- Net income
- −$28.4M
No dividends on record.
| Institutions | 23.63% | 9.47M ADS | |
|---|---|---|---|
| 82 holders · as of Jun 30, 2026 | |||
| Insiders | 1.42% | 567.3K ADS | |
| 5 holders · as of Sep 9, 2026 | |||
| Strategic holders | 42.65% | 17.10M ADS | |
| 1 holder · as of Jan 21, 2025 | |||
| Other | 32.30% | 12.95M ADS | |
| remainder | |||
40.09M ADS as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2024 annual report; nothing newer is on file here.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Lin Bioscience International Ltd.Strategic | 42.65% | 17.10M | filed Jan 21, 2025 |
Darwin Global Management, Ltd.Institution | 7.68% | 3.08M ADS | as of Jun 30, 2026 |
Paradigm Biocapital Advisors LPInstitution | 3.08% | 1.23M ADS | as of Jun 30, 2026 |
RTW Investments, LPInstitution | 1.78% | 715,332 ADS | as of Jun 30, 2026 |
Millennium Management LLCInstitution | 1.23% | 494,564 ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 8, 2026 | Hao-Yuan Chuang | director, officer: Chief Financial Officer | −17,962 | $196.42 |
| Sep 4, 2026 | Hao-Yuan Chuang | director, officer: Chief Financial Officer | −49,433 | $187.64 |
| Sep 8, 2026 | Yu-Hsin Lin | director, officer: Chief Executive Officer | −26,000 | $196.56 |
| Sep 4, 2026 | Yu-Hsin Lin | director, officer: Chief Executive Officer | −74,435 | $187.71 |
| Aug 12, 2026 | Yu-Hsin Lin | director, officer: Chief Executive Officer | −365 | $180.35 |
- Biogen
Controls SYFOVRE, a commercial intravitreal therapy for GA
- Ocugen
Advances OCU410ST gene therapy in a pivotal STGD1 trial
- Annexon
Advances Phase 3 vonaprument for GA vision preservation
- Lineage Cell Therapeutics
Develops RG6501 (OpRegen), a cell therapy for GA
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Belite Bio (ADR) | $176.60 | +1.85% | $6.95B | — | — | — | — |
| Biogen | $221.92 | +1.30% | $32.37B | 38.8 | 16.7 | 3.3 | +3.4% |
| Ocugen | $1.06 | +2.91% | $349.3M | — | — | 76.3 | +8.4% |
| Annexon | $4.26 | +0.83% | $691.4M | — | — | — | — |
| Lineage Cell Therapeutics | $1.01 | 0.00% | $251.8M | — | — | 19.2 | −61.3% |
| Median | 38.8 | 16.7 | 19.2 | +3.4% |